New drugs and targets for asthma and COPD

New Drugs and Targets for Asthma and COPD

Volumn 39, Issue , 2010, Pages 3-23

  Hansel, Trevor T ^a   Barnes, Peter J ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925944501     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000320793     Document Type: Chapter

References (384)

1. Eder W, Ege MJ, von ME. The asthma epidemic. N Engl J Med 2006, 355(21): 2226-35.
2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM. et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007, 370(9589): 741-50.
3. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007, 4(5): e112.
4. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370(9589): 765-73.
5. National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI). Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. www.ginasthma.com. Updated 2007.
6. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368(9537): 804-13.
7. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87.
8. National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI), World Health Organisation (WHO). Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.com. Updated 2007.
9. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007, CD006103.
10. Oncken C, Gonzales D, Nides M, Rennard S et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006, 166(15): 1571-7.
11. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007, CD005353.
12. Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007, 47: 541-64.
13. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-19.
14. Barnes PJ, Adcock IM. Glucocorticoid resistance in infl ammatory diseases. Lancet 2009;373:1905-17.
15. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009;374:744-55.
16. Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet 2007, 370(9589): 774-85.
17. Medoff BD, Thomas SY, Luster AD. T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol 2008, 26: 205-32.
18. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8(3): 183-92.
19. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007, 119(5): 1055-62.
20. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372(9643): 1107-19.
21. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008, 372(9643): 1073-87.
22. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8(3): 218-30.
23. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006, 129(1): 151-5.
24. Cosio BG, Mann B, Ito K et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004, 170(2): 141-7.
25. Deykin A. Biomarker-driven care in asthma: are we there? J Allergy Clin Immunol 2006, 118(3): 565-8.
26. Battaglia S, den HH, Timmers MC et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005, 60(8): 7'.
27. Ueda T, Niimi A, Matsumoto H et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006, 118(5): 1019-25.
28. Van Schoor J, Pauwels R, Joos G. Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges. Clin Exp Allergy 2005, 35(3): 250-61.
29. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol 2006, 118(3): 551-9.
30. Honey K. Translating medical science around the world. J Clin Invest 2007, 117(10): 2737.
31. Farre R, nh-Xuan AT. Translational research in respiratory medicine. Eur Respir J 2007, 30(6): 1041-2.
32. National Center for Research Resources, National Institutes of Health (NIH). Clinical and Translational Science Awards (CTSA). http://www.ncrr.nih.gov/clinical_research_resources/clinical_and_translational_science:awards. Acessed March 30, 2009.
33. Innovative Medicines Initiative (IMI). http://imi.europa.eu/index_en.html. Accessed March 30, 2009.
34. National Institutes of Health (NIH). Biomedical Research Centres. J Clin Invest 2006.
35. Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31(2): 416-69.
36. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offl ine measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005, 171: 912-30.
37. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006, 61(9): 817-27.
38. Horvath I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26(3): 523-48.
39. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE (Eds). Standardised methodology of sputum induction and processing. European Respiratory Society Task Force. Eur Respir J 2002, 20: 1s-55s.
40. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360(9347): 1715-21.
41. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of medicinal products in the treatment of asthma. CPMP/EWP/2922/01 2002.
42. EMEA CPMP. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). Human Medicines Evaluation Unit, European Medicines Evaluation Agency (EMEA) 1999, CPMP/EWP 562/98.
43. U.S. Dept of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft Guidance for industry: Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment. http://www.fda.gov/cder/guidance/index.htm 2007.
44. Hansel TT, Erin EM, Barnes PJ. The allergen challenge. Clin Exp Allergy 2002, 32(2): 162-7.
45. Parameswaran K, Inman MD, Watson RM et al. Protective effects of fl uticasone on allergen-induced airway responses and sputum infl ammatory markers. Can Respir J 2000, 7(4): 313-9.
46. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8): 775-89.
47. Bousquet J, Van Cauwenberge P, Khalttaev N and the WHO Panel. Allergic rhinitis and its impact on asthma. ARIA. In collaboration with the World Health Organization. J Allergy Clin Immunol 2001, 108: S1-S315.
48. Bousquet J, Van CP, Ait KN, Bachert C et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN).Allergy 2006, 61(9): 1086-96.
49. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approxmation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Commun 2001, L121: 34-44.
50. U.S. Dept of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Allergic Rhinitis: Clinical Development Programs for Drug Products. www.fda.gov/cder/guidance/index.htm 2000.
51. Ministry of Health Canada. Release of Draft Guidance Document: Submission Requirements for Subsequent Market Entry Inhaled Corticosteroid Products for Use in the Treatment of Asthma. File Number: 07-118017-24 2007.
52. EMEA CPMP. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. CPMP/EWP/4151/00 Rev 1 2009.
53. Juniper EF, Guyatt GH, Ferrie PJ et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993, 147(4): 832-8.
54. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991, 85(Suppl B): 25-31.
55. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995, 107(6): 1585-9.
56. Meltzer EO, Hamilos DL, Hadley JA et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006, 118(5 Suppl.): S17-61.
57. National Institutes of Health (NIH). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69: 89-95.
58. Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31(2): 416-69.
59. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005, 26(2): 319-38.
60. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.
61. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166: 111-7.
62. Palange P, Ward SA, Carlsen KH et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007, 29(1): 185-209.
63. ATS/ERS Recommendations for standardized procedures for the online and offl ine measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. 2005. Am J Respir Crit Care Med 2005, 171: 912-30.
64. Busse WW, Wanner A, Adams K et al. Investigative bronchoprovocation andbronchoscopy in airway diseases. Am J Respir Crit Care Med 2005, 172(7): 807-16.
65. Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004;24:481-92.
66. Donaldson GC, Wedzicha JA. COPD exacerbations. Epidemiology. Thorax 2006, 61(2): 164-8.
67. Jones P, Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. Proc Am Thorac Soc 2007, 4(8): 597-601.
68. European Medicines Evaluation Agency (EMEA). Guideline on the Requirments for Clinical Documentations for Orally Inhaled Products (OIP) including the Requirements for Demonstration of Therapeutic Equivalence between two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for use in the Treatment of Asthma in Children and Adolescents. CPMP/EWP/4151/00 Rev 1 2009.
69. Rabe KF, Hurd S, Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6): 532-55.
70. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14(7): 775-83.
71. Matera MG, Cazzola M. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007, 67(4): 503-15.
72. Davies SL, Castaner J. Indacterol. Drugs Fut 2005, 30: 1219-24.
73. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy1H-quinolin-2-0ne (indacterol), a novel beta2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006, 317(2): 762-70.
74. Beier J, Chanez P, Martinot JB et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2006, 20(6): 740-9.
75. Beeh KM, Derom E, Kanniess F et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-hour bronchodilation in asthma. Eur Respir J 2007, 29(5): 871-8.
76. Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008, 102(7): 1033-44.
77. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005, 27(4): 377-92.
78. Hansel TT, Neighbour H, Erin EM. et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005, 128(4): 1974-9.
79. van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airfl ow obstruction and resting hyperinfl ation in patients with COPD. Chest 2006, 129(3): 509-17.
80. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003, 139(5, Pt. 1): 359-70.
81. Reynolds NA, Scott LJ. Ciclesonide. Drugs 2004, 64(5): 511-9.
82. Pearlman DS, Berger WE, Kerwin E. et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005, 116(6): 1206-12.
83. Barnes PJ. How corticosteroids control infl ammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006, 148(3): 245-54.
84. Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004, 101(1): 227-32.
85. Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med 2000, 161(2, Pt. 2): S2-S6.
86. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway infl ammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003, 111(1 Suppl.): S18-S34.
87. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway infl ammation. J Allergy Clin Immunol 2006, 118(4): 789-98.
88. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med 2007, 13(1): 24-30.
89. Poff CD, Balazy M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Infl amm Allergy 2004, 3(1): 19-33.
90. Park GY, Christman JW. Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of infl ammatory lung diseases. Am J Physiol Lung Cell Mol Physiol 2006, 290: L797-L805.
91. Hicks A, Monkarsh SP, Hoffman AF et al. Leukotriene B4 receptor antagonists as therapeutics for infl ammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007, 16(12): 1909-20.
92. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007, 6(4): 313-25.
93. Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur J Pharmacol 2006, 533(1-3): 215-21.
94. Schelfhout V, Louis R, Lenz W et al. The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulm Pharmacol Ther 2006, 19(6): 413-8.
95. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5(3): 247-64.
96. Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008, 153(Suppl. 1): S446-56.
97. Devillier P. Comparing the new antihistamines: the role of pharmacological parameters. Clin Exp Allergy 2006, 36(1): 5-7.
98. Leurs R, Bakker RA, Timmerman H, de Esch I. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005, 4(2): 107-20.
99. Dunford PJ, Williams KN, Desai PJ et al. Histamine H(4) receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007, 119(1): 17683.
100. Obiefuna PC, Batra VK, Nadeem A et al. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxyethyl)-amino]- ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005, 315(1): 329-36.
101. Matera MG, Polosa R. Adenosine receptors: novel targets for drug development in allergic rhinitis. Clin Exp Allergy 2007, 37(1): 4-7.
102. Rimmer J, Peake HL, Santos CM et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2007, 37(1): 8-14.
103. Trifilieff A, Keller TH, Press NJ et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-infl ammatory activities. Br J Pharmacol 2005, 144(7): 1002-10.
104. Holgate ST, Djukanovic R, Casale T et al. Anti-immunoglobulin E treatment withomalizumabin allergic diseases: an update on anti-infl ammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35(4): 408-16.
105. Poole JA, Matangkasombut P, Rosenwasser LJ. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 2005, 115(3): S376-85.
106. Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155(6): 1828-34.
107. Fahy JV, Cockcroft DW, Boulet L-P et al. Effects of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Resp Crit Care Med 1999, 160(3): 1023-7.
108. Milgrom H, Fick RB, Jr., Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 1999, 341(26): 1966-73.
109. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60(3): 309-16.
110. Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34(4): 632-8.
111. Ayres JG, Higgins B, Chilvers ER et al. Efficacy and tolerability of antiimmunoglobulin E therapy withomalizumab in patients with poorly controlled (moderateto-severe) allergic asthma. Allergy 2004, 59(7): 701-8.
112. Bousquet J, Cabrera P, Berkman N et al. The effect of treatment withomalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60(3): 302-8.
113. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006,354(25): 2689-95.
114. Finn A, Gross G, van Bavel J et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003, 111(2): 278-84.
115. Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002, 20(5): 1088-94.
116. Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18(2): 254-61.
117. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108(2): 184-90.
118. Casale TB, Busse WW, Kline JN. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117(1): 134-40.
119. Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109(2): 274-80.
120. Leung DY, Sampson HA, Yunginger JW et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348(11): 986-93.
121. Poole JA, Meng J, Reff M et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005, 116(4): 780-8.
122. Rosenwasser LJ, Meng J. Anti-CD23. Clin Rev Allergy Immunol 2005, 29(1): 61-72.
123. Rosenwasser LJ, Busse WW, Lizambri RG et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003, 112(3): 563-70.
124. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005, 116(5): 961-8.
125. Wohlleben G, Erb KJ. Atopic disorders: a vaccine around the corner? Trends Immunol 2001, 22(11): 618-26.
126. Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol 2006, 6(11): 869-74.
127. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6(10): 761-71.
128. Durham SR, Yang WH, Pedersen MR. et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117(4): 802-9.
129. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118(2): 434-40.
130. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007, 119(4): 906-9.
131. Racila DM, Kline JN. Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol 2005, 116(6): 12025.
132. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9:293-307.
133. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweedtoll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355(14): 1445-55.
134. Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy 2003, 33(10): 1330-5.
135. Silverman ES, Drazen JM. Immunostimulatory DNA for asthma: better than eating dirt. Am J Respir Cell Mol Biol 2003, 28(6): 645-7.
136. Kitagaki K, Businga TR, Kline JN. Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin Exp Immunol 2006, 143(2): 249-59.
137. Beasley R, Shirtcliffe P, Harper JL et al. Mycobacterium-based vaccines for the prevention of allergic disease: a progress report. Clin Exp Allergy 2002, 32(8): 1128-30.
138. Matricardi PM, Yazdanbakhsh M. Mycobacteria and atopy, 6 years later: a fascinating, still unfinished, business. Clin Exp Allergy 2003, 33(6): 717-20.
139. Elias JA, Homer RJ, Hamid Q, Lee CG. Chitinases and chitinase-like proteins in T(H)2 infl ammation and asthma. J Allergy Clin Immunol 2005, 116(3): 497-500.
140. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(6): 471-84.
141. Gauvreau GM, Hessel EM, Boulet LP et al. Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses. Am J Respir Crit Care Med 2006, 174(1): 15-20.
142. Hamelmann E, Gelfand EW. IL-5-induced airway eosinophilia--the key to asthma? Immunol Rev 2001, 179: 182-91.
143. Sampson AP. IL-5 priming of eosinophil function in asthma. Clin Exp Allergy 2001, 31(4): 513-7.
144. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000, 356(9248): 2144-8.
145. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001, 108(4): 503-8.
146. Hansel TT, Sterk PJ, Holgate ST, Barnes PJ Letter to Editor: The trials and tribulations of anti-IL5. J Allergy Clin Immunol 2002, 109(3): 575.
147. Flood-Page PT, Menzies-Gow AN, Kay AB et al. Eosinophil's role remains uncertain as anti-Interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167(2): 199-204.
148. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112(7): 1029-36.
149. Phipps S, Flood-Page P, Menzies-Gow A et al. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 2004, 122(6): 1406-12.
150. Kips JC, O'Connor BJ, Langley SJ et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167(12): 1655-9.
151. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and effi-cacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176(11): 1062-71.
152. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349(21): 2014-22.
153. Oldhoff JM, Darsow U, Werfel T et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005, 60(5): 693-6.
154. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
155. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
156. Wenzel SE. Eosinophils in asthma - closing the loop or opening the door? N Engl J Med 2009;360:1026-8.
157. Plotz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003, 349(24): 2334-9.
158. Klion AD, Law MA, Noel P et al. Safety and efficacy of the monoclonal antiinterleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103(8): 2939-41.
159. Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358(12): 1215-28.
160. Stein ML, Collins MH, Villanueva JM et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118(6): 1312-9.
161. Braun-Falco M, Fischer S, Plotz S-G RJ. Correspondence: Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). J Dermatol 2004, 151: 1103-13.
162. Borish LC, Nelson HS, Lanz MJ et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160(6): 1816-23.
163. Borish LC, Nelson HS, Corren J et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107(6): 963-70.
164. Reddel H, Ware S, Marks G et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999, 353(9150): 364-9.
165. Malavia NK, Mih JD, Raub CB et al. IL-13 induces a bronchial epithelial phenotype that is profibrotic. Respir Res 2008, 9: 27.
166. Blanchard C, Mishra A, Saito-Akei H et al. Inhibition of human interleukin-13-induced respiratory and oesophageal infl ammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005, 35(8): 1096-103.
167. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004, 202:175-90.
168. Wenzel S, Wilbraham D, Fuller R et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370(9596): 1422-31.
169. Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004, 25(4): 201-9.
170. Baughman RP, Drent M, Kavuru M et al. Infl iximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7): 795-802.
171. Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFa) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60(12): 1012-8.
172. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354(7): 697-708.
173. Erin EM, Leaker BR, Nicholson GC et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006, 174(7): 753-62.
174. Morjaria JB, Chauhan AJ, Babu KS et al. The role of a soluble TNF-a receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008, 63(7): 584-91.
175. He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-a. Science 2005, 310(5750): 1022-5.
176. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infl iximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9): 926-34.
177. Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9): 866-7.
178. Lambrecht BN, Kuipers H, van Rijt L et al. Dendritic cells in the pathogenesis of ashtma. Clin Exp All Rev 2004, 4: 123-8.
179. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic infl ammation. J Exp Med 2006, 203(2): 269-73.
180. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int 2008, 57(1): 1-10.
181. Bogiatzi SI, Fernandez I, Bichet JC et al. Cutting edge: Proinfl ammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol 2007, 178(6): 3373-7.
182. Morand EF, Leech M, Bernhagen J. MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006, 5(5): 399-410.
183. Ishiguro Y, Ohkawara T, Sakuraba H et al. Macrophage migration inhibitory factor has a proinfl ammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol 2006, 120(3): 335-41.
184. Gregory JL, Morand EF, McKeown SJ et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 2006, 177(11): 8072-9.
185. Kudrin A, Scott M, Martin S et al. Human macrophage migration inhibitory factor: a proven immunomodulatory cytokine? J Biol Chem 2006, 281(40): 29641-51.
186. Toh ML, Aeberli D, Lacey D et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 2006, 177(7): 4818-25.
187. Wang B, Huang X, Wolters P. et al. Cutting edge: Deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol 2006, 177(9): 5779-84.
188. Kitaichi N, Shimizu T, Honda A et al. Increase in macrophage migration inhibitory factor levels in lacrimal fl uid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol 2006, 244(7): 825-8.
189. Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 2006, 45(8): 937-43.
190. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for infl ammatory disorders. Drugs Today (Barc) 2006, 42(9): 559-76.
191. O'Byrne P, Boulet LP, Gaureau G et al. A single dose of MEDI-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. Chest 2007, 132: 478S (Abstract).
192. Devos S, Cormont F, Vrtala S et al. Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. Clin Exp Allergy 2006, 36(2): 174-82.
193. McNamara PS, Flanagan BF, Baldwin LM et al. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Lancet 2004, 363(9414): 1031-7.
194. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006, 36(4): 465-74.
195. Ruckert R, Brandt K, Braun A et al. Blocking IL-15 prevents the induction of allergen-specific T cells and allergic infl ammation in vivo. J Immunol 2005, 174(9): 5507-15.
196. Kawaguchi M, Adachi M, Oda N et al. IL-17 cytokine family. J Allergy Clin Immunol 2004, 114(6): 1265-73.
197. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 2006, 19(3): 245-52.
198. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in infl ammation. J Clin Invest 2006, 116(5): 1218-22.
199. Guyatt GH, Berman LB, Townsend M et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42(10): 773-8.
200. Letuve S, Lajoie-Kadoch S, Audusseau S et al. IL-17E upregulates the expression of proinfl ammatory cytokines in lung fibroblasts. J Allergy Clin Immunol 2006, 117(3): 590-6.
201. Linden A. Interleukin-17 and airway remodelling. Pulm Pharmacol Ther 2006, 19(1): 47-50.
202. Sergejeva S, Ivanov S, Lotvall J, Linden A. Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway infl ammation. Am J Respir Cell Mol Biol 2005, 33(3): 248-53.
203. Linden A, Laan M, Anderson GP. Neutrophils, interleukin-17A and lung disease. Eur Respir J 2005, 25(1): 159-72.
204. Sebelova S, Izakovicova-Holla L, Stejskalova A et al. Interleukin-18 and its three gene polymorphisms relating to allergic rhinitis. J Hum Genet 2007, 52(2): 152-8.
205. Kumano K, Nakao A, Nakajima H et al. Interleukin-18 enhances antigeninduced eosinophil recruitment into the mouse airways. Am J Resp Crit Care Med 1999, 160(3): 873-8.
206. Petersen AMW, Penkowa M, Iversen M et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 2007, 185: 161-71.
207. McKay A, Komai-Koma M, Macleod KJ et al. Interleukin-18 levels in induced sputum are reduced in asthmatic and normal smokers. Clin Exp Allergy 2004, 34(6): 904-10.
208. Cebeci AN, Nuhoglu Y, Arslanoglu I et al. The role of IL-18 in Th1/Th2 balance in children. Allergy Asthma Proc 2006, 27(4): 365-70.
209. Fina D, Fantini MC, Pallone F, Monteleone G. Role of interleukin-21 in infl ammation and allergy. Infl amm Allergy Drug Targets 2007, 6(1): 63-8.
210. Hiromura Y, Kishida T, Nakano H et al. IL-21 administration into the nostril alleviates murine allergic rhinitis. J Immunol 2007, 179(10): 7157-65.
211. Kishida T, Hiromura Y, Shin-Ya M et al. IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J Immunol 2007, 179(12): 8554-61.
212. Barnes PJ. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 2003, 14(6): 511-22.
213. Kennedy NS, Barnstein B, Brenzovich J et al. IL-10 Suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 2008, 180: 2848-54.
214. Bryan SA, O'Connor BJ, Matti S et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 2000, 356: 2153.
215. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006, 27(10): 546-53.
216. Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Infl amm Allergy 2005, 4(3): 313-7.
217. Smit JJ, Lukacs NW. A closer look at chemokines and their role in asthmatic responses. Eur J Pharmacol 2006, 533(1-3): 277-88.
218. Homey B, Steinhoff M, Ruzicka T et al. Cytokines and chemokines orchestrate atopic skin infl ammation. J Allergy Clin Immunol 2006, 118(1): 178-89.
219. Wells TN, Power CA, Shaw JP et al. Chemokine blockers--therapeutics in the making? Trends Pharmacol Sci 2006, 27(1): 41-7.
220. Pease JE. Asthma, allergy and chemokines. Curr Drug Targets 2006, 7(1): 3-12.
221. Main S, Handy R, Wilton J et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther 2006, 319(3): 1395-404.
222. Hogaboam CM, Lukacs NW, Chensue SW et al. Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4+ T cell activation. J Immunol 1998, 160(9): 4606-14.
223. Jin Q, Nie H, McCleland BW et al. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor. Bioorg Med Chem Lett 2004, 14(17): 4375-8.
224. Nouri-Aria KT, Wilson D, Francis JN et al. CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 2002, 32(7): 1933-8.
225. Kaur D, Saunders R, Berger P et al. Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am J Respir Crit Care Med 2006, 174(11): 1179-88.
226. Sen Y, Yongyi B, Yuling H et al. V alpha 24-invariant NKT cells from patients with allergic asthma express CCR9 at high frequency and induce Th2 bias of CD3+ T cells upon CD226 engagement. J Immunol 2005, 175(8): 4914-26.
227. Mahler DA, Huang S, Tabrizi M et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004, 126(3): 926-34.
228. Costa C, Rufino R, Traves SL et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008, 133(1): 26-33.
229. Bochner BS. Adhesion molecules as therapeutic targets. Immunol Allergy Clin North Am 2004, 24(4): 615-30, vi.
230. Vanderslice P, Biediger RJ, Woodside DG et al. Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm Pharmacol Ther 2004, 17(1): 1-10.
231. Romano SJ. Selectin antagonists: Therapeutic potential in asthma and COPD. Respir Med 2005, 4: 85-94.
232. Meyer M, Jilma B, Zahlten R et al. Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. Int J Clin Pharmacol Ther 2005, 43(10): 463-471.
233. Beeh KM, Beier J, Meyer M et al. Bimosiamose, an inhaled small-molecule panselectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical crossover-trial. Pulm Pharmacol Ther 2006, 19(4): 233-41.
234. Kranich R, Busemann AS, Bock D et al. Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem 2007, 50(6): 1101-15.
235. Avila PC, Boushey HA, Wong H et al. Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses. Clin Exp Allergy 2004, 34(1): 77-84.
236. Meyer M, Beeh KM, Beier J et al. Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males. Br J Clin Pharmacol 2007, 63(4): 451-8.
237. Singh J, Adams S, Carter MB et al. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr Top Med Chem 2004, 4(14): 1497-507.
238. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med 2005, 353(4): 414-6.
239. Drazen JM. Patients at risk. N Engl J Med 2005, 353(4): 417.
240. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353(4): 369-74.
241. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353(4): 375-81.
242. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005, 4(6): 510-8.
243. Norris V, Choong L, Tran D et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2005, 116(4): 761-7.
244. Sedgwick JB, Jansen KJ, Kennedy JD et al. Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions. J Allergy Clin Immunol 2005, 116(4): 812-9.
245. Giembycz MA. Can the anti-infl ammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008, 155(3): 288-90.
246. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365(9454): 167-75.
247. Ouagued M, Martin-Chouly CA, Brinchault G et al. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. Pulm Pharmacol Ther 2005, 18(1): 49-54.
248. Compton CH, Gubb J, Nieman R et al. Cilomilast, a selective phosphodiesterase4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001, 358(9278): 265-70.
249. Rennard SI, Schachter N, Strek M et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006, 129(1): 56-66.
250. van Schalkwyk E, Strydom K, Williams Z et al. Rofl umilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005, 116(2): 292-8.
251. Bousquet J, Aubier M, Sastre J et al. Comparison of rofl umilast, an oral antiinfl ammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006, 61(1): 72-8.
252. Bateman ED, Izquierdo JL, Harnest U et al. Efficacy and safety of rofl umilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006, 96(5): 679-86.
253. Timmer W, Leclerc V, Birraux G et al. The new phosphodiesterase 4 inhibitor rofl umilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002, 42(3): 297-303.
254. van SE, Strydom K, Williams Z et al. Rofl umilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005, 116(2): 292-8.
255. Schmidt BM, Kusma M, Feuring M et al. The phosphodiesterase 4 inhibitor rofl umilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001, 108(4): 530-6.
256. Rabe KF, Bateman ED, O'Donnell D et al. Rofl umilast-an oral antiinfl ammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2005, 366(9485): 563-71.
257. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Rofl umilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
258. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Rofl umilast in moderateto-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
259. O'Byrne PM, Gauvreau G. Phosphodiesterase-4 inhibition in COPD. Lancet 2009;374:665-7.
260. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with rofl umilast, a new phosphodiesterase 4 inhibitor. COPD 2010;7:141-53.
261. Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor rofl umilast in patients with COPD. Thorax 2007, 62(12): 1081-87.
262. Calverley PM, Sanchez-Toril F, McIvor A et al. Effect of 1-year treatment with rofl umilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176(2): 154-61.
263. Peter D, Jin SL, Conti M et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007, 178(8): 4820-31.
264. Smith SJ, Cieslinski LB, Newton R et al. Discovery of BRL 50481 [3-(N,Ndimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ Tlymphocytes. Mol Pharmacol 2004, 66(6): 1679-89.
265. Giembycz MA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2: 326-33.
266. Ariga M, Neitzert B, Nakae S et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of infl ammation. J Immunol 2004, 173(12): 7531-38.
267. Robichaud A, Stamatiou PB, Jin SL et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110(7): 1045-52.
268. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005, 10(22): 1503-19.
269. Mehats C, Jin SL, Wahlstrom J et al. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 2003, 17(13): 1831-41.
270. Kuss H, Hoefgen N, Johanssen S et al. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fl uorobenzyl)-5-hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307(1): 373-85.
271. Trifilieff A, Keller TH, Press NJ et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-infl ammatory activities. Br J Pharmacol 2005, 144(7): 1002-10.
272. Giembycz MA, Smith SJ. Phosphodiesterase 7A: A new therapeutic target for alleviating chronic infl ammation? Curr Pharm Des 2006, 12(25): 3207-20.
273. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung infl ammation in COPD. Eur Respir J 2006, 28(1): 219-42.
274. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006, 111(2): 476-94.
275. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5(6): 493-506.
276. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: The myofi-broblast in focus. Chest 2007, 132(4): 1311-21.
277. Hudson TJ. Dornase in treatment of chronic bronchitis. Ann Pharmacother 1996, 30(6): 674-75.
278. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet 2008, 371(9629): 2013-18.
279. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebocontrolled trial. Lancet 2005, 365(9470): 1552-60.
280. Woodruff PG, Wolff M, Hohlfeld JM, et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:438-45.
281. Hu J, Van den Steen PE, Sang QX et al. Matrix metalloproteinase inhibitors as therapy for infl ammatory and vascular diseases. Nat Rev Drug Discov 2007, 6(6): 480-98.
282. Churg A, Wang R, Wang X et al. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007, 62(8): 706-13.
283. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9:129-40.
284. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006, 368(9537): 780-93.
285. Koli K, Myllarniemi M, Keski-Oja J et al. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008, 10(2): 333-42.
286. Wang IM, Stepaniants S, Boie Y et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008, 177(4): 402-11.
287. Leung SY, Niimi A, Noble A et al. Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway infl ammation and remodeling. J Pharmacol Exp Ther 2006, 319(2): 58694.
288. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for infl ammatory diseases. Eur J Pharmacol 2006, 533(1-3): 327-40.
289. Dolgachev V, Berlin AA, Lukacs NW. Eosinophil activation of fibroblasts from chronic allergen-induced disease utilizes stem cell factor for phenotypic changes. Am J Pathol 2008, 172(1): 68-76.
290. Wong F. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr Opin Pharmacol 2005, 5: 264-71.
291. Heymach JV, Nilsson M, Blumenschein G et al. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006, 12(14, Pt. 2): 4441s-5s.
292. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006, 6(4): 409-21.
293. Cazzola M, Matera MG, Rogliani P et al. Treating systemic effects of COPD. Trends Pharmacol Sci 2007, 28(10): 544-50.
294. Celli BR. Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc 2006;3:461-5.
295. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:857-64.
296. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704-11.
297. Simpson JL, Powell H, Boyle MJ et al. Clarithromycin targets neutrophilic airway infl ammation in refractory asthma. Am J Respir Crit Care Med 2008, 177(2): 148-55.
298. Johnston SL, Blasi F, Black PN et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006, 354(15): 1632-4.
299. The IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102: 531-7.
300. Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143(4): 532-40.
301. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2(1): 44-9.
302. Jain MK, Ridker PM. Anti-Infl ammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nat Rev Drug Discov 2005, 4(12): 977-87.
303. Alexeeff SE, Litonjua AA, Sparrow D et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007, 176(8): 742-7.
304. Blamoun AI, Batty GN, DeBari VA et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62(9): 1373-8.
305. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005, 25(4): 634-9.
306. Soyseth V, Brekke PH, Smith P et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29(2): 279-83.
307. Frost FJ, Petersen H, Tollestrup K et al. Infl uenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131(4): 100612.
308. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12): 2554-60.
309. van Gestel YR, Hoeks SE, Sin DD et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008, 102(2): 192-6.
310. Yang IA, Fong KM, Sim EH et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, CD002991.
311. Suissa S, Ernst P, Vandemheen KL et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008, 31(5): 927-33.
312. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006, 533(1-3): 2-14.
313. Ito K, Yamamura S, Essilfie-Quaye S et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006, 203(1): 7-13.
314. Barnes PJ. Theophylline for COPD. Thorax 2006, 61(9): 742-4.
315. Cosio BG, Tsaprouni L, Ito K et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200(5): 689-95.
316. Chatila TA, Li N, Garcia-Lloret M et al. T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. J Allergy Clin Immunol 2008, 121(4): 812-23.
317. Cousins DJ, McDonald J, Lee TH. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008, 121(4): 803-9.
318. Adcock IM, Chung KF, Caramori G et al. Kinase inhibitors and airway infl ammation. Eur J Pharmacol 2006, 533(1-3): 118-32.
319. O'Neill LA. Targeting signal transduction as a strategy to treat infl ammatory diseases. Nat Rev Drug Discov 2006, 5(7): 549-63.
320. Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006, 109(1-2): 238-45.
321. Barnes PJ. Transcription factors in airway diseases. Lab Invest 2006, 86(9): 867-72.
322. D'Acquisto F, Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 2006, 6(4): 387-92.
323. Birrell MA, Hardaker E, Wong S et al. Ikappa-B kinase-2 inhibitor blocks infl ammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 2005, 172(8): 962-71.
324. Birrell MA, Wong S, Hardaker EL et al. IkappaB kinase-2-independent and -dependent infl ammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006, 69(6): 1791-800.
325. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3(1): 17-26.
326. Tudhope SJ, Catley MC, Fenwick PS et al. The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gammastimulated human bronchial epithelial cells. J Immunol 2007, 179(9): 6237-45.
327. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for infl ammatory diseases. Nat Rev Drug Discov 2003, 2(9): 717-26.
328. Birrell MA, Wong S, McCluskie K et al. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of infl ammatory mediator production in human and rodent airways. J Pharmacol Exp Ther 2006, 316(3): 1318-27.
329. Renda T, Baraldo S, Pelaia G et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31(1): 62-9.
330. Smith SJ, Fenwick PS, Nicholson AG et al. Inhibitory effect of p38 mitogenactivated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006, 149(4): 393-404.
331. Medicherla S, Fitzgerald MF, Spicer D et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces infl ammation in a subchronic model of tobacco smoke-induced airway infl ammation. J Pharmacol Exp Ther 2008, 324(3): 921-9.
332. Wong BR, Grossbard EB, Payan DG et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004, 13(7): 743-62.
333. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: Key regulators of phagocytic cell activation. Trends Immunol 2005, 26(4): 208-14.
334. Stenton GR, Ulanova M, Dery RE et al. Inhibition of allergic infl ammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002, 169(2): 1028-36.
335. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005, 115(4): 791-6.
336. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006, 34(2): 97-115.
337. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004, 114(1): 13-9.
338. Brightling CE, Bradding P, Pavord ID et al. New insights into the role of the mast cell in asthma. Clin Exp Allergy 2003, 33(5): 550-6.
339. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006, 6(1): 65-75.
340. Jensen BM, Metcalfe DD, Gilfillan AM. Targeting kit activation: a potential therapeutic approach in the treatment of allergic infl ammation. Infl amm Allergy Drug Targets 2007, 6(1): 57-62.
341. Capdeville R, Buchdunger E, Zimmermann J et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1(7): 493-502.
342. Quintas-Cardama A, Aribi A, Cortes J et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006, 107(7): 1429-39.
343. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348(13): 1201-14.
344. Scheinfeld N. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol 2006, 5(2): 117-22.
345. Berlin AA, Hogaboam CM, Lukacs NW. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Lab Invest 2006, 86(6): 557-65.
346. Nilsson G, Hjertson M, Andersson M et al. Demonstration of mast-cell chemotactic activity in nasal lavage fl uid: characterization of one chemotaxin as c-kit ligand, stem cell factor. Allergy 1998, 53(9): 874-9.
347. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway infl ammation. Eur J Pharmacol 2006, 533(1-3): 101-9.
348. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung infl ammation and repair. Proc Am Thorac Soc 2005, 2(3): 226-31.
349. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-_ agonists as potential anti-infl ammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006, 36(12): 1494-504.
350. Becker J, Delayre-Orthez C, Frossard N et al. Regulation of infl ammation by PPARs: a future approach to treat lung infl ammatory diseases? Fundam Clin Pharmacol 2006, 20(5): 429-47.
351. Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an "aspirin of the 21st century"? Nat Rev Drug Discov 2006, 5(11): 903-18.
352. Remels AH, Schrauwen P, Broekhuizen R et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007, 30(2): 245-52.
353. Tudhope SJ, Finney-Hayward TK, Nicholson AG et al. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 2008, 324(1): 306-12.
354. Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: Leucocytes and beyond. Immunology 2007, 121(4): 448-61.
355. Ward S, Sotsios Y, Dowden J et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003, 10(3): 207-13.
356. Ulanova M, Schreiber AD, Befus AD. The future of antisense oligonucleotides in the treatment of respiratory diseases. BioDrugs 2006, 20(1): 1-11.
357. Sel S, Henke W, Dietrich A et al. Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologies. Curr Pharm Des 2006, 12(25): 3293-304.
358. Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005, 9(4): 840-53.
359. Bumcrot D, Manoharan M, Koteliansky V et al. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2(12): 711-9.
360. Fortin M, Ferrari N, Higgins ME et al. Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. Oligonucleotides 2006, 16(3): 203-12.
361. Allakhverdi Z, Allam M, Guimond A et al. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann N Y Acad Sci 2006, 1082: 62-73.
362. Gauvreau GM, Boulet LP, Cockcroft DW et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177(9): 952-8.
363. Gauvreau GM, Hessel EM, Boulet LP et al. Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses. Am J Respir Crit Care Med 2006, 174(1): 15-20.
364. Bitko V, Musiyenko A, Shulyayeva O et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11(1): 50-5.
365. Musiyenko A, Bitko V, Barik S. RNAi-dependent and -independent antiviral phenotypes of chromosomally integrated shRNA clones: Role of VASP in respiratory syncytial virus growth. J Mol Med 2007, 85(7): 745-52.
366. Barik S, Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006, 6(11): 1151-60.
367. Griesenbach U, Kitson C, Escudero GS. et al. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res 2006, 7: 26.
368. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997, 3(6): 675-7.
369. Stinchcombe SV, Maden M. Retinoic acid induced alveolar regeneration: critical differences in strain sensitivity. Am J Respir Cell Mol Biol 2008, 38(2): 185-91.
370. Roth MD, Connett JE, D'Armiento JM et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006, 130(5): 1334-45.
371. Conese M, Rejman J. Stem cells and cystic fibrosis. J Cyst Fibros 2006, 5(3): 141-3.
372. Griffiths MJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet 2005, 366(9481): 249-60.
373. Polak JM, Bishop AE. Stem cells and tissue engineering: past, present, and future. Ann N Y Acad Sci 2006, 1068: 352-66.
374. Klimanskaya I, Rosenthal N, Lanza R. Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat Rev Drug Discov 2008, 7(2): 131-42.
375. Sueblinvong V, Weiss DJ. Cell therapy approaches for lung diseases: current status. Curr Opin Pharmacol 2009;9:268-73.
376. Wang D, Haviland DL, Burns AR et al. A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2007, 104(11): 4449-54.
377. Loebinger MR, Janes SM. Stem cells for lung disease. Chest 2007, 132(1): 279-85.
378. Dardalhon V, Awasthi A, Kwon H et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9(12): 1347-55.
379. Veldhoen M, Uyttenhove C, van Snick J, Helmby H et al. Transforming growth factor-beta "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9(12): 1341-6.
380. Tato CM, Cua DJ. Alternative lifestyles of T cells. Nat Immunol 2008, 9(12): 1323-5.
381. Zhou L, Lopes JE, Chong MM et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453(7192): 236-40.
382. Mucida D, Park Y, Kim G et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317(5835): 256-60.
383. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009;461:218-23.
384. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35:564-70.